Preparing evidence view. Loading the requested ADMETatlas route.
ADMETatlas — Peptide ADMET Evidence Atlas
Skip to content Product, clinical, identity, immune-recognition, BBB, and label context kept near the evidence view without converting it into comparable endpoint measurements.
Dimensions 6 ·
Shown 1-20 Context dimensions Context grouped by scientific dimension of the drug. Counts do not imply effect size, evidence strength, or clinical risk.
All dimensions (3,678)
ADMETatlas is an open, curated atlas of ADMET evidence for therapeutic peptides — spanning developability, membrane permeability and blood–brain-barrier transport, immune-recognition context, and approved-product context. Every measurement stays linked to its original source, with stable identifiers and transparent curation, so results can be traced, cited, and reproduced.
Resources Developability Atlas
Drug identity RxNorm / RxNav identity normalization, names, and candidate identity matches.
Interpretation boundary Study-registry context (phase, status, enrollment); not endpoint evidence.
Context entries Viewing 1-20 of 2,753 matching context entries.
# NCT Study title Phase Status Enrollment Results ID Source 1 NCT04666129 Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer PHASE1 COMPLETED 48 No ATLXS0000002 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
© 2026 ADMETatlas, an academic peptide ADMET evidence atlas.
Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma
PHASE3
COMPLETED
400
No
ATLXS0000003
Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese
PHASE2
NOT YET RECRUITING
224
No
ATLXS0000004
Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
PHASE2
COMPLETED
14
Yes
ATLXS0000007
Physical Activity and Food Intake Interaction: Effect of Weight Loss in Obese Adolescent
not reported
COMPLETED
20
No
ATLXS0000008
Pharmacokinetics of Afamelanotide in Erythropoietic Protoporphyria Patients
PHASE1|PHASE2
COMPLETED
28
Yes
ATLXS0000009
Oxytocin Antagonist in Patients With Repeated Failure of Implantation
PHASE4
COMPLETED
138
No
ATLXS0000010
Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia
PHASE2
COMPLETED
54
Yes
ATLXS0000012
A Study on the Impact of Bivalirudin Usage During PCI for High-risk Plaques on Post-PCI Coronary Microcirculation.
PHASE4
RECRUITING
70
No
ATLXS0000013
Effects of Desmopressin on Blood Loss and the Quality of the Surgical Field During Endoscopic Sinus Surgery
PHASE4
COMPLETED
60
No
ATLXS0000019
A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes
PHASE4
COMPLETED
112
Yes
ATLXS0000020
Vasopressin and V2 Receptor in Meniere's Disease
not reported
COMPLETED
135
No
ATLXS0000023
A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
PHASE3
COMPLETED
231
Yes
ATLXS0000024
Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS), in Adult Renal Transplant Patients in Maintenance.
PHASE3
COMPLETED
30
Yes
ATLXS0000027
Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus
PHASE4
COMPLETED
124
Yes
ATLXS0000028
A Study of Degarelix in Taiwanese Patients With Prostate Cancer
PHASE3
COMPLETED
110
Yes
ATLXS0000031
HEALEY ALS Platform Trial - Master Protocol
PHASE2|PHASE3
RECRUITING
1500
No
ATLXS0000032
A Dose-ranging Safety and Efficacy Study of Ecallantide to Reduce Surgical Blood Loss Volume
PHASE2
COMPLETED
276
Yes
ATLXS0000036
Tocolytic Therapy for Preterm Labor in Multiple Gestation
PHASE3
UNKNOWN
140
No
ATLXS0000037
Micro Glucagon During Exercise in Type 1 Diabetes
EARLY PHASE1
WITHDRAWN
0
No
ATLXS0000042
